### Edgar Filing: ORAMED PHARMACEUTICALS INC. - Form 4

ORAMED Form 4 April 11, 20	PHARMACEUTI	CALS INC	2.							
FORM	ЛЛ								PPROVA	۹L
-	UNITED	STATES S		RITIES A			E COMMISSION	N OMB Number:		-0287
Section 16. Form 4 or Form 5 Filed pursuant to obligations may continue. 20(h)			F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Section 16(a) of the Securities Exchange Act of 1934, Public Utility Holding Company Act of 1935 or Section of the Investment Company Act of 1940					Estimated burden hou response	stimated average rden hours per	
<i>See</i> Inst 1(b).	ruction	00(11)0			compu		.,			
(Print or Type	Responses)									
1. Name and Address of Reporting Person <u>*</u> Kidron Miriam			2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ORMP]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
			3. Date of Earliest Transaction (Month/Day/Year)				XDirector10% Owner XOfficer (give titleOther (specify below) below)			
2 ELZA S	FREET	(	04/09/2	2014			· · · · · · · · · · · · · · · · · · ·	Technology Off	ficer	
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>				
JERUSAL	EM, L3 93706						Person	More than One R	eporting	
(City)	(State)	(Zip)	Tab	le I - Non-I	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owne	d
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3,	(A) or of (D)	Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature Indirect Beneficia Ownersh (Instr. 4)	al 1ip
Pamindar: Pa	aport on a senarate line	for each clas	s of soo							
Kennider: Ke	port on a separate line	FIOT CACH CHAS	55 01 Sect	unnes bene	Perso inforr requi	ons who re nation con red to resp ays a curre	spond to the colle tained in this form ond unless the fo antly valid OMB co	n are not rm	SEC 1474 (9-02)	

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

8 L S

#### Edgar Filing: ORAMED PHARMACEUTICALS INC. - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Year	) (Instr. 8)	or Dispose (D)	(Instr. 3, 4,				(
			Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 12.45	04/09/2014	А	47,134		<u>(1)</u>	04/09/2024	Common Stock	47,134

## **Reporting Owners**

Reporting Owner Name / Addr	·ess		Relationships	
	Director	10% Owner	Officer	Other
Kidron Miriam 2 ELZA STREET JERUSALEM, L3 93706	Х		Chief Technology Officer	
Signatures				
/s/ Miriam Kidron	04/11/2014			

<u>\*\*</u>Signature of Reporting Person

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

Date

- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Stock Option will vest with respect to 15,710 shares on April 30, 2014 and with respect to 3,928 shares on the last day of each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

(